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FibroblastsConnective tissue growth factor (CTGF) plays an important role in lung ﬁbrosis. In this study, we investigated the
role of Rac1, mixed-lineage kinase 3 (MLK3), c-Jun N-terminal kinase (JNK), and activator protein-1 (AP-1) in
CTGF-induced collagen I expression in human lung ﬁbroblasts. CTGF caused concentration- and time-
dependent increases in collagen I expression. CTGF-induced collagen I expression was inhibited by the dominant
negative mutant (DN) of Rac1 (RacN17), MLK3DN, MLK3 inhibitor (K252a), JNK1DN, JNK2DN, a JNK inhibitor
(SP600125), and an AP-1 inhibitor (curcumin). Treatment of cells with CTGF caused activation of Rac1, MLK3,
JNK, and AP-1. The CTGF-induced increase in MLK3 phosphorylation was inhibited by RacN17. Treatment with
RacN17 and the MLK3DN inhibited CTGF-induced JNK phosphorylation. CTGF caused increases in c-Jun phos-
phorylation and the recruitment of c-Jun and c-Fos to the collagen I promoter. Furthermore, stimulation of
cells with the CTGF resulted in increases in AP-1-luciferase activity; this effect was inhibited by Rac1N17,
MLK3DN, JNK1DN, and JNK2DN. Moreover, CTGF-induced α-smooth muscle actin (α-SMA) expression was
inhibited by the procollagen I small interfering RNA (siRNA). These results suggest for theﬁrst time that CTGF act-
ing through Rac1 activates the MLK3/JNK signaling pathway, which in turn initiates AP-1 activation and recruit-
ment of c-Jun and c-Fos to the collagen I promoter and ultimately induces collagen I expression in human lung
ﬁbroblasts.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Pulmonary ﬁbrosis develops in many lung inﬂammatory diseases,
and it may progress to end-stage lung disease [1]. The most common
variation of this disease is idiopathic pulmonary ﬁbrosis, which is lungﬁ-
brosis from unknown causes [2,3]. Additionally, certain airway diseases,
such as asthma, involve a signiﬁcant degree of tissue remodeling orosis signal-regulating kinase 1;
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ights reserved.pulmonary ﬁbrosis [4]. Pulmonary ﬁbrosis involves the overgrowth,
hardening, and scarring of lung tissue due to excess extracellular matrix
(ECM) deposition such as by collagen [5,6]. Fibroblasts, major regulator
cells of collagen turnover in adult connective tissue, are recruited to
the wound site by the release of inﬂammatory mediators such as
transforming growth factor-β (TGF-β), platelet-derived growth factor,
interleukin-6 (IL-6), and IL-8/CXCL8 [7,8]. Previous studies indicated
that ﬁbroblasts express no or only low levels of connective tissue growth
factor (CTGF). However, the CTGF is induced during wound healing and
by mediators such as TGF-β or thrombin that contribute to scar forma-
tion and pulmonary ﬁbrosis [9,10].
The CTGF belongs to the CCN family, is a recently identiﬁed
proﬁbrotic agent, and is involved in lung ﬁbrosis and tissue repair
[11,12]. The CTGF was implicated in ﬁbroblast proliferation, cellular ad-
hesion, angiogenesis, and ECM synthesis [11]. It is expressed in different
types of cells such as epithelial cells, vascular smooth muscle cells, and
lung ﬁbroblasts [10,11]. Elevated CTGF expression contributes to ex-
pression of α-smooth muscle actin (α-SMA) and the myoﬁbroblast
phenotype in tissue repair or development of connective tissues
[13,14]. Our previous study reported that thrombin induced CTGF
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nase 1 (ASK1)/c-JunN-terminal kinase (JNK)/activator protein-1 (AP-1)
dependent pathway [10]. Another report showed that the CTGF partic-
ipates in bleomycin-induced collagen expression and lung ﬁbrosis
[15]. Wang et al. [16] has demonstrated that the CTGF promotes the de-
velopment of ﬁbrosis in collaboration with TGF-β in animal models.
Moreover, the CTGF induced human hypertrophic scar ﬁbroblast prolif-
eration through Janus kinase (JAK)/signal transducer and activator of
transcription (STAT) signaling pathway and plays an important role in
scar ﬁbrosis and contraction [17]. Therefore, the CTGF was proposed
as being a potential key proﬁbrotic marker for tissue ﬁbrosis including
of the dermis and lungs. A previous report has showed that CTGF-
induced collagen expression occurs through a JNK pathway [15].
However, the molecular mechanism underlying CTGF activates JNK-
mediated collagen expression in human lung ﬁbroblasts is poorly
understood.
The ECM is comprised of numerousmultifaceted structures that pro-
vide structural integrity to connective tissues. The building blocks of the
ECM consist of collagens, glycoproteins (ﬁbronectins, tenascins, and
ﬁbrillins), and glycoaminoglycans [18]. The ECM acts as a “skeleton”
onto which cell can adhere and grow, maneuver, and differentiate.
The most abundant proteins in the ECM are members of the collagen
family [18]. Type I collagen is themost plentiful and well-studiedmem-
ber of the collagen family; it is classiﬁed as one of the ﬁbrillar collagens
and is one of the most widely expressed proteins in the body; it is a
major constituent of the skin, bones, and numerous interstitial connec-
tive tissues [5]. Themain function of collagen I is to provide strength and
elasticity to connective tissues [5]. Recent study demonstrated that
collagen-dependent cellular processes known to be involved in the de-
velopment of lung ﬁbrosis including ﬁbroblast proliferation, migration,
and differentiation [19,20]. The promoter region of the human collagen
I gene contains many transcription factor-binding sites including
CCAAT/enhancer-binding protein β (c/EBPβ), Smads, SP1/SP3, and AP-
1 [21]. A previous study demonstrated that TGF-β-induced collagen ex-
pression is mediated by the Smad 3 signal pathway in human dermal ﬁ-
broblasts [22]. Another report showed that angiotensin II stimulated
collagen expression through AP-1 signaling in human dermal ﬁbro-
blasts [23]. However, the role of AP-1 in regulating collagen I expression
by CTGF stimulation in human lung ﬁbroblasts is still unknown.
A recent report established a role for certain small GTP-binding pro-
teins controlling the enzymatic activity of a family of closely related
mitogen-activated protein kinases (MAPKs) [24]. In turn, MAPKs phos-
phorylate and regulate the activity of key molecules that ultimately
control expressions of genes essential for many cellular processes, in-
cluding pulmonary ﬁbrosis [15]. Previous studies showed that Rac1, a
Rho family of small GTP-binding proteins, regulates the activity of JNK
[24,25]. Rac1 exists in an inactive (GDP-bound) state until signals
such as cellular stress, growth factors, or G-protein receptor activation
converts it into an active (GTP-bound) state [26]. The binding of GTP in-
duces a conformational change in Rac1, which promotes its association
with a diverse array of downstream effectors including mixed-lineage
kinase 3 (MLK3) [25]. MLK3 is aMAPK kinase kinase (MAPKKK) and be-
longs to the MLK family [27]. MLK family members are characterized
by the presence of highly conserved sequences of serine/threonine
(Ser/Thr) within their catalytic domain. They can be divided into three
subgroups, MLK1-4, dual leucine-zipper bearing kinases, and zipper
sterile a-motif kinases [28]. Phosphorylation of MLKs was shown to ac-
tivate MAPKKs and MAPKs [29]. A previous report indicated that MLK3
is required for mitogen activation of Raf, extracellular signal-regulated
kinase (ERK), and JNK signaling, and for MAPK-dependent cell prolifer-
ation in different cell types [30]. One recently identiﬁed Rac1-interactor
protein is the multi-domain scaffold protein plenty of SH3s, which reg-
ulates JNK signaling by forming a complex with JNK and MLK3 [31].
Moreover, Engers et al. [32] reported that a Rac-dependent AP-1 activa-
tion signaling pathwaymediates tissue inhibitor ofmetalloproteinase-1
expression in a human renal carcinoma. Based on this evidence, weinvestigated the role of Rac1 and its signaling pathway in CTGF-
induced MLK3/JNK/AP-1 activation and collagen I expression in
human lung ﬁbroblasts. In this study, we demonstrated that CTGF acts
through Rac1 to initiate the downstreamactivation ofMLK3/JNK signal-
ing pathways, which in turn initiate c-Jun/AP-1 activation and recruit-
ment to the collagen I promoter, and ultimately induce collagen I
expression in human lung ﬁbroblasts.
2. Materials and methods
2.1. Materials
The CTGFwas purchased from Sigma (St. Louis, MO, USA). SP600125
and K252a were purchased from Tocris Bioscience (Avonmouth, UK).
Minimum Essential Medium (MEM), fetal calf serum (FCS), penicillin/
streptomycin, sodium pyruvate, L-glutamine, non-essential amino
acids (NEAAs), and the Lipofectamine Plus reagent were purchased
from Invitrogen Life Technologies (Gaithersburg,MD, USA). An antibody
speciﬁc for α-tubulin was purchased from Transduction Laboratories
(Lexington, KY, USA). Antibodies speciﬁc for JNK dually phosphorylated
at Thr183/Tyr185 and MLK3 dually phosphorylated at Thr277/Ser281
were purchased from Cell Signaling Technology (St. Louis, MO, USA).
Control small interfering RNA (siRNA), procollagen I siRNA, protein
A/G beads, antibodies speciﬁc for JNK, c-Jun, c-Jun phosphorylated at
Ser63, c-Fos, and α-SMA, and anti-mouse, anti-rabbit, and anti-goat
IgG-conjugated HRP were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). A chromatin immunoprecipitation (ChIP) assay
kit, Rac1 expression construct sequences carrying the T17N (dominant
negative, RacN17)mutation, and a Rac activity assay kit were purchased
from Upstate Biotech Millipore (Lake Placid, NY, USA). The collagen I
primers were obtained from Genomics (New Taipei City, Taiwan).
The expression construct for the MLK3 wild-type (MLK3WT) and
dominant negative mutant of MLK3 (MLK3DN) were kindly provided
by Dr. J. Woodgett (Samuel Lunenfeld Research Institute, Toronto,
Ontario, Canada). The JNK1DN, JNK2DN, and pcDNA were provided by
Dr. M.-C. Chen (Taipei Medical University, Taipei, Taiwan). pBK-CMV-
Lac Z (LacZ) was provided by Dr. W-W. Lin (National Taiwan University,
Taipei, Taiwan). All materials for SDS-PAGE were purchased from Bio-
Rad. All other chemicals were obtained from Sigma.
2.2. Cell culture
WI-38 cells, a normal human embryonic lung ﬁbroblast cell line,
were obtained from American Type Culture Collection (ATCC). Cells
were grown in an MEM nutrient mixture, containing 10% FCS,
2 mM L-glutamine, 0.1 mM NEAAs, 1 mM sodium pyruvate, 50 U/ml
penicillin G, and 100 μg/ml streptomycin, in a humidiﬁed 37 °C incuba-
tor with 5% CO2. Cells were used between passages 18 and 30 for all ex-
periments. After reaching conﬂuence, cells were seeded onto 6-cm
dishes for cell transfection and immunoblotting; onto 10-cm dishes
for the ChIP assay; and onto 12-well plates for the cell transfection
and luciferase assays.
2.3. Western blot analysis
Western blot analyses were performed as described previously [33].
Brieﬂy, WI-38 cells were cultured in 6-cm dishes. After reaching conﬂu-
ence, cells were treated with the vehicle and thrombin, or pretreated
with speciﬁc inhibitors as indicated followed by thrombin.Whole-cell ly-
sates (50 μg) were subjected to SDS-PAGE, and transferred onto a
polyvinylidene diﬂuoride membrane which was then incubated in TBST
buffer (150 mM NaCl, 20 mM Tris-HCl, and 0.02% Tween 20; pH 7.4)
containing 5%bovine serumalbumin. Proteinswere visualized by speciﬁc
primary antibodies and then incubated with HRP-conjugated secondary
antibodies. Immunoreactivity was detected using enhanced chemilumi-
nescence (ECL) following the manufacturer's instructions. Quantitative
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aging system (Eastman Kodak Rochester, NY, USA).
2.4. Transfection and AP-1-luciferase assays
WI-38 cells (5 × 104 cells/well) were seeded onto 12-well plates,
and cells were transfected the following day using Lipofectamine Plus
with 0.5 μg of AP-1-Luc and 0.5 μg of Lac Z. After 6 h, the medium was
aspirated, replaced with basal medium devoid of FBS, and incubated
overnight, after which cells were stimulated with thrombin for another
16 h before being harvested. To assay the effects of RacN17, MLK3DN,
JNK1DN, and JNK2DN, cells were cotransfected with AP-1-Luc, Lac Z,
and either RacN17,MLK3DN, JNK1DN, or JNK2DN, and the level of lucif-
erase activity was determined. Luciferase activity was determined with
a luciferase assay system (Promega), andwas normalized on the basis of
Lac Z expression. The level of induction of luciferase activity was com-
puted as the ratio of cells with and without stimulation.
2.5. ChIP assay
ChIP assays were performed using a ChIP assay kit according to the
manufacturer's instructions. Brieﬂy, WI-38 cells (2 × 106 cells) were in-
cubatedwith the CTGF (30 ng/ml) for 30 min and then cross-linkedwith
formaldehyde at 37 °C for another 10 min. Cell lysates were sonicated
and then centrifuged for 10 min at 15,000 ×g at 4 °C to spin down the
cell debris. Soluble cross-linked chromatins were immunoprecipitatedFig. 1. Collagen I expression by connective tissue growth factor (CTGF) inWI-38 ﬁbroblasts. Cel
(30 ng/ml) for the indicated time intervals (B). Cellswere lysed and then immunoblottedwith a
intensities ofα-tubulin. Traces represent results from three independent experiments, which a
ulation. (C) Cells were pretreated for 30 min with an equivalent vehicle control (DMSO), 1 μM
CTGF for another 4 h. Cellswere lysed and then immunoblottedwith antibodies speciﬁc for colla
presented as the mean ± SEM. * p b 0.05, compared to the CTGF-treated group. (D) Cells were
(Act.D) and then stimulatedwith 30 ng/ml CTGF for another 2 h. Total RNAwas prepared, and a
from three independent experiments.with anti-c-Jun, anti-c-Fos, and anti-rabbit IgG antibodies. DNA was pu-
riﬁed and eluted with 50 μl of elution buffer using a spinning ﬁlter. Poly-
merase chain reaction (PCR) ampliﬁcations of the AP-1 response
elements on the collagen promoter regionwere performed using the fol-
lowing primers: AP-1, 5′-CCT AAG GCA TAG AGC AAT GAC-3′ (sense)
and 5′-GGT GAG AAA CAT GAC TAG GTG-3′ (antisense). Extracted
DNA (2 μl) was used for 45 cycles of ampliﬁcation in 50 μl of reaction
mixture under the following conditions: 95 °C for 30 s, 58 °C for 60 s,
and 72 °C for 30 s. The PCR products were analyzed by 2% agarose gel
electrophoresis.2.6. Rac activity assay
Rac activity was measured using a Rac activity assay kit. The assay
was performed according to the manufacturer's instructions. Brieﬂy,
cells were washed twice with ice-cold PBS, lysed in 1 ml of magnesium
lysis buffer (MLB) (25 mM HEPES (pH 7.5), 150 mM NaCl, 5% igepal
CA-630, 10 mM MgCl2, 5 mM EDTA, 10% glycerol, 10 μg/ml aprotinin,
and 10 μg/ml leupeptin), and centrifuged at 14,000 ×g for 30 min. The
lysate (0.8 ml) was incubated with 5 μg of PAK1 p21-binding domain
(PBD)-agarose at 4 °C overnight. The beads were washed three times
with MLB lysis buffer and centrifuged at 8000 ×g for 5 min. Bound
Rac proteinswere then solubilized in 20 μl of 2× Laemmli sample buffer
and quantitatively detected byWestern blotting (12% SDS-PAGE) using
a mouse monoclonal anti-Rac antibody with the ECL system.ls were incubated with vehicle or various concentrations of CTGF for 4 h (A) or with CTGF
ntibodies speciﬁc for collagen I orα-tubulin. Equal loading in each lane is shown by similar
re presented as the mean ± SEM. * p b 0.05, compared to the control without CTGF stim-
actinomycin D (Act.D), or 1 μM cycloheximide (CHX) and then stimulated with 30 ng/ml
gen I orα-tubulin Traces represent results from three independent experiments, whichare
pretreated for 30 min with an equivalent vehicle control (DMSO) or 1 μM actinomycin D
RT-PCRwere carried out as described in “Materials andMethods”. Traces represent results
Fig. 2. Rac1 is involved in connective tissue growth factor (CTGF)-induced collagen I ex-
pression in WI-38 ﬁbroblasts. (A) Cells were transiently transfected with either 1 μg of
pcDNA (mock) or 0.5 or 1 μg of RacN17 for 24 h. The levels of Rac1 and α-tubulin protein
expression were determined by a Western blot analysis. Traces represent results from
three independent experiments. (B) Cells were transiently transfected with either 1 μg
of pcDNA (mock) or 0.5 or 1 μg of RacN17 for 24 h and then stimulated with 30 ng/ml
CTGF for another 4 h. Cells were lysed and then immunoblotted with antibodies speciﬁc
for collagen I or α-tubulin Traces represent results from three independent experiments,
which are presented as themean ± SEM. * p b 0.05, compared to the CTGF-treated group.
(C) For Rac activity, cells were treated with vehicle or 30 ng/ml CTGF for the indicated
time intervals, and cell lysates were then immunoprecipitated with PDK-1 PBD-agarose.
The Rac activity is described in “Materials and methods”. Rac1 and α-tubulin protein
levels were determined in total lysates by a Western blot analysis as the loading control.
Traces represent results from three independent experiments with similar results.
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To amplify human ﬁbroblast collagen I mRNA speciﬁc primers were
synthesized. The collagen I primers used were: sense 5′-CCC GGG TTT
CAG AGA CAA CTT C-3′ and antisense 5′-TCC ACA TGC TTT ATT CCA
GCA ATC-3′. β-actin mRNA levels were used as an internal control.
The β-actin primers used were: sense 5′-GAC TAC CTC AAG ATC CT-3′
and antisense 5′-CCA CAT CTG GAA GGT GG-3′. WI-38 cells were cul-
tured onto 6-cm dishes. After reaching conference, themediumwas as-
pirated and replaced with basal medium devoid of FBS overnight, after
which, cell were pretreated with actinomycin D (1 μM) for 30 min
and then stimulatedwithCTGF (30 ng/ml) for another 2 h. The puriﬁca-
tion of total RNA and RT-PCR were carried out using a direct RT-PCR kit
(Yeastern Biotech, Taipei, Taiwan), according to the manufacturer's in-
structions. Equal amounts (5 μg of cDNA) of each PCR product were
PCR-ampliﬁed with RealStart polymerase in 40 cycles consisting of
30 s at 95 °C, 30 s at 58 °C, and 30 s at 72 °C. The ampliﬁed cDNA was
run on 2% agarose gels and visualized with ethidium bromide. The
cDNA samples were also used to generate β-actin PCR products and
their amount was considered as internal control.
2.8. Statistical analysis
Results are presented as the mean ± SEM from at least three inde-
pendent experiments. One-way analysis of variance (ANOVA) followed
byDunnet's test was usedwhen appropriate to determine the statistical
signiﬁcance of the difference between means. Values of p b 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. CTGF induces collagen I expression
A previous study showed that CTGF participates in bleomycin-
induced collagen expression and lung ﬁbrosis in a mice model [15]. In
the present study, we investigated whether CTGF can induce collagen
I expression in human lung ﬁbroblasts (WI-38). Incubation of cells
with CTGF (3–100 ng/ml) for 4 h induced collagen I expression in a
concentration-dependent manner, with a maximum effect at 30 ng/ml
CTGF treatment (Fig. 1A). Similarly, this induction occurred in a time-
dependent manner (Fig. 1B). After treatment, the collagen I protein
began to appear at 1 h, reached amaximumat 4 h, and then gradually di-
minished to 24 h (Fig. 1B). After 4 h of treatment with CTGF (30 ng/ml),
the collagen I protein had increased by 4.1 ± 0.8-fold (Fig. 1B). In the fol-
lowing experiments, WI-38 cells were treated with 30 ng/ml of CTGF for
4 h. Next, to determine whether CTGF-induced collagen I expression
occurred through de novo synthesis, a transcriptional inhibitor (actino-
mycin D) and a translational inhibitor (cyclohexamide) were used.
We found that pretreatment ofWI-38 ﬁbroblasts with 1 μMactinomycin
D or 1 μM cyclohexamide both almost completely inhibited CTGF-
induced collagen I protein expression (Fig. 1C). Moreover, 1 μM actino-
mycin D also completely attenuated CTGF-induced collagen I mRNA ex-
pression (Fig. 1D). These results suggest that the increase in collagen I
expression in WI-38 cells responsive to CTGF was dependent on
de novo synthesis.
3.2. Rac1 is involved in CTGF-induced collagen I expression
Small G proteins such as Rac1 were shown to participate in the sig-
naling pathway leading to induction of ﬁbroblast collagen expression
with bleomycin treatment [34]. To investigate the possible role of Rac1
in the mediation of CTGF-induced collagen I expression in lung ﬁbro-
blasts, the Rac1 expression construct for the dominant negative Rac1-
T17N mutant (RacN17) was used. First, we tested the level of RacN17
protein expression by transfection of cells with RacN17 plasmid. Based
on the Western blot analysis using speciﬁc antibody to Rac1, Rac1protein was highly expressed in RacN17 plasmid-transfected WI-38
cells compared to the pcDNA plasmid-transfected WI-38 cells (control
group) (Fig. 2A). Moreover, transfection of cells with RacN17 (0.5 and
1 μg) inhibited CTGF-induced collagen I expression in a concentration-
dependent manner, with 1 μg of RacN17, reducing CTGF-induced colla-
gen I expression by 81 ± 7% (n = 3) (Fig. 2B). To further elucidate
whether Rac1 activation is involved in the signaling cascade of CTGF-
induced collagen I expression, Rac activity was measured after CTGF ex-
posure. Treatment of WI-38 cells with CTGF (30 ng/ml) induced an in-
crease in Rac activity in a time-dependent manner, as assessed by
immunoblot samples for Rac1 immunoprecipitated from lysates using
PAK1 PBD-agarose. The response had begun at 1 min andwas sustained
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activation is involved in CTGF-induced collagen I expression.
3.3. Involvement of MLK3 in CTGF-induced collagen I expression
Rac1may activate a number of signal pathways includingMLK3 [25].
Depending on the cellular context,MLK3was implicated in inﬂammato-
ry gene expression [35]. To examine whether MLK3 activation is
involved in the signal transduction pathway leading to collagen I ex-
pression caused by CTGF, K252a (an MLK3 inhibitor) and MLK3DN
were used. As shown in Fig. 3A, pretreatment of cells with K252a
(0.1–10 nM) markedly attenuated CTGF-induced collagen I expression.
When cells were treated with 10 nM K252a, CTGF-induced collagen I
expression was inhibited by 82 ± 6% (n = 3) (Fig. 3A). In addition,
transfection of WI-38 cells with 0.25 and 0.5 μg of MLK3DN almost
completely attenuated CTGF-induced collagen I expression (Fig. 3B).
Similar to CTGF stimulation, transfection of WI-38 cells with 0.5 μg of
the MLK3 wild-type plasmid (MLK3WT) caused increases in collagen I
expression (Fig. 3C). Moreover, the levels of MLK3 protein was highly
expressed in MLK3DN plasmid- or MLK3WT plasmid-transfectedFig. 3.Mixed-lineage kinase 3 (MLK3) is involved in connective tissue growth factor (CTGF)-in
equivalent vehicle control (DMSO) or K252a (0.1–10 nM) (A) or transfectedwith either 0.5 μg o
for 24 h and then incubated with the CTGF (30 ng/ml) for another 4 h. Cells were lysed and the
sults from three independent experiments, which are presented as themean ± SEM. * p b 0.05
0.5 μg of MLK3 wild-type (WT), or CTGF (30 ng/ml) for 4 h. Cells were lysed and then immun
three independent experiments, which are presented as the mean ± SEM. * p b 0.05, compare
(mock), 0.25 or 0.5 μg of MLK3DN, or 0.5 μg of MLK3 WT for 24 h. The levels of MLK3 and α-
results from three independent experiments.WI-38 cells compared to the pcDNA plasmid-transfecetd WI-38 cells
(Fig. 3D). These results indicated that MLK3 plays an important role in
collagen I expression in human lung ﬁbroblasts. Phosphorylation of
MLK3 at the Thr277 and Ser281 residues causes enzymatic activation
[36]. Next, we measured MLK3 Thr277/Ser281 phosphorylation in re-
sponse to the CTGF. Fig. 4A shows that treatment of WI-38 cells with
CTGF (30 ng/ml) induced an increase in MKL3 Thr277/Ser281 phos-
phorylation in a time-dependent manner. This response began at
3 min, peaked at 5 min, and declined to 30 min after CTGF stimulation
(Fig. 4A, upper panel). The protein level of MLK3 was not affected by
CTGF treatment (Fig. 4A, lower panel). Furthermore, CTGF-induced
MLK3 phosphorylation was markedly inhibited by transfection of cells
with 1 μg RacN17 by 68 ± 8% (n = 3) (Fig. 4B). Taken together, these
results indicate that MLK3 is a downstream molecule of Rac1 in CTGF-
induced collagen I expression.
3.4. JNK activation is involved in CTGF-induced collagen I expression
A previous study demonstrated that upstream activation of MLK3
regulates the JNK signaling pathway [37]. Next, in an attempt toduced collagen I expression inWI-38 ﬁbroblasts. Cells were pretreated for 30 min with an
f pcDNA (mock) or 0.25 or 0.5 μg of the dominant negativemutant ofMLK3 (MLK3DN) (B)
n immunoblotted with antibodies speciﬁc for collagen I orα-tubulin. Traces represent re-
, compared to the CTGF-treated group. (C) Cells were treatedwith 0.5 μg of pcDNA (mock),
oblotted with antibodies speciﬁc for collagen I or α-tubulin. Traces represent results from
d to the pcDNA group. (D) Cells were transiently transfected with either 0.5 μg of pcDNA
tubulin protein expression were determined by a Western blot analysis. Traces represent
Fig. 4. Involvement of Rac1 in connective tissue growth factor (CTGF)-inducedmixed-line-
age kinase 3 (MLK3) Thr277/Ser281 phosphorylation in WI-38 ﬁbroblasts. (A) Cells were
incubated with vehicle or CTGF (30 ng/ml) for 0–30 min. MLK3 Thr277/Ser281 phosphor-
ylation was shown by immunoblotting with antibodies speciﬁc for phosphorylated MLK3
Thr277/Ser238. Equal loading in each lane is shown by the similar intensities of MLK3.
Traces represent results from three independent experiments, which are presented as the
mean ± SEM. * p b 0.05, compared to the control without CTGF stimulation. (B) Cells
were transiently transfected with either 1 μg of pcDNA or 1 μg of RacN17 for 24 h and
then stimulated with 30 ng/ml CTGF for another 5 min. Cells were lysed and then
immunoblotted with antibodies speciﬁc for phosphorylated MLK3 Thr277/Ser238 or
MLK3. Traces represent results from three independent experiments, which are presented
as the mean ± SEM. * p b 0.05, compared to the control with the CTGF-treated group.
Fig. 5. Involvement of c-Jun N-terminal kinase (JNK) in connective tissue growth factor
(CTGF)-induced collagen I expression in WI-38 ﬁbroblasts. Cells were pretreated for
30 min with an equivalent vehicle control (DMSO) or SP600125 (1–10 μM) (A) or
transfected with either 0.5 μg of pcDNA (mock), 0.5 μg of the dominant negative mutant
of JNK1 (JNK1DN), or 0.5 μg of JNK2DN (B) for 24 h and then incubated with the CTGF
(30 ng/ml) for another 4 h. Cellswere lysed and then immunoblottedwith antibodies spe-
ciﬁc for collagen I or α-tubulin Traces represent results from three independent experi-
ments, which are presented as the mean ± SEM. * p b 0.05, compared to the CTGF-
treated group. (C) Cells were transiently transfected with either 1 μg of pcDNA (mock),
0.5 μg of JNK1DN, or 0.5 μg of JNK2DN for 24 h. The levels of JNK andα-tubulin protein ex-
pression were determined by a Western blot analysis. Traces represent results from three
independent experiments.
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collagen I expression, SP600125 (a JNK inhibitor) was used. As shown
in Fig. 5A, CTGF-induced collagen I expression was concentration-
dependently attenuated by SP600125 (1–10 μM). Pretreatment of
cells with 10 μM SP600125 inhibited CTGF-induced collagen I expres-
sion by 93 ± 16% (n = 3) (Fig. 5A). To further conﬁrm that JNK medi-
ates CTGF-induced collagen I expression, the JNK1DN and JNK2DNwere
used. Transfection of cells with the JNK1DN (0.5 μg) and JNK2DN
(0.5 μg) completely attenuated CTGF-induced collagen I expression
(Fig. 5B). The levels of JNK protein were highly expressed in JNK1DN
plasmid- and JNK2DN plasmid-transfected WI-38 cells compared to
the pcDNA plasmid-transfecetd WI-38 cells (Fig. 5C). Because dual
phosphorylation of Thr183 and Tyr185 of JNK results in an increase in
JNK activation [38], an antibody speciﬁc against phosphorylated JNK
(Thr183/Tyr185) was used to examine JNK phosphorylation. When
cells were treated with the CTGF (30 ng/ml) for various time intervals,
JNK Thr183/Tyr185 phosphorylation increased at 2 min, peaked at
10 min, and declined after 30 min of treatment (Fig. 6A, upper panel).However, the protein level of JNK was not affected by CTGF treatment
(Fig. 6A, lower panel). To determine the relationships among Rac1,
MLK3, and JNK in the CTGF-mediated signaling pathway, cells
transfected with RacN17 (0.5 μg) and MLK3DN (0.5 μg) markedly
inhibited CTGF-induced JNK Thr183/Tyr185 phosphorylation by 57 ±
Fig. 6. Involvement of Rac1 and mixed-lineage kinase 3 (MLK3) in connective tissue
growth factor (CTGF)-induced c-JunN-terminal kinase (JNK) phosphorylation inWI-38ﬁ-
broblasts. (A) Cells were incubatedwith vehicle or the CTGF (30 ng/ml) for 0–60 min. JNK
Thr183/Tyr185 phosphorylationwas shown by immunoblottingwith an antibody speciﬁc
for phosphorylated JNK Thr183/Tyr185. Equal loading in each lane is shown by similar in-
tensities to that of JNK. Traces represent results from three independent experiments,
which are presented as the mean ± SEM. * p b 0.05, compared to the control without
CTGF stimulation. (B) Cells were transiently transfected with either 0.5 μg of pcDNA,
0.5 μg of RacN17, or 0.5 μg of the dominant negative mutant of MLK3 (MLK3DN) for
24 h and then stimulated with 30 ng/ml CTGF for another 10 min. Cells were lysed and
then immunoblotted with antibodies speciﬁc for phosphorylated JNK Thr183/Tyr185 or
JNK. Traces represent results from three independent experiments, which are presented
as the mean ± SEM. * p b 0.05, compared to the control with the CTGF-treated group.
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sults, we suggest that activations of Rac1 and MLK3 occur upstream of
JNK in CTGF-induced collagen I expression.
3.5. AP-1 mediates CTGF-induced collagen I expression
As mentioned previously, AP-1 activation is necessary for collagen I
induction [39]. To examine whether AP-1 activation is involved in the
signaling transduction pathway leading to collagen I expression caused
by the CTGF, the AP-1 inhibitor, curcumin, was used. As shown in
Fig. 7A, CTGF-induced collagen I expressionwas attenuated by curcumin
(1–10 μM) in a concentration-dependent manner. In cells treated with
10 μM curcumin, CTGF-induced collagen I expression was almost
completely abolished (Fig. 7A). This result suggests that AP-1 activation
is involved in CTGF-induced collagen I expression. AP-1 generally con-
sists of heterodimers of c-Jun and c-Fos proteins [40]. Because serinephosphorylation of residue 63 of c-Jun by JNK results in an increase in
AP-1 transcription activity [10,41], an antibody speciﬁc against phos-
phorylated c-Jun Ser63 was used to examine c-Jun phosphorylation. As
a result, when cells were treated with 30 ng/ml CTGF for various time
intervals, c-Jun Ser63 phosphorylation increased at 5 min, peaked at
30 min, and declined after 60 min of treatment (Fig. 7B, upper panel).
The protein level of c-Jun was not affected by CTGF treatment (Fig. 7B,
lower panel). To determine whether the AP-1 subunits, c-Jun and
c-Fos, are recruited to the endogenous collagen I promoter region in re-
sponse to CTGF, ChIP experiments were performed onWI-38 cells stim-
ulatedwith CTGF. Treatment ofWI-38 cellswith 30 ng/ml CTGF induced
an increase in recruitment of c-Jun and c-Fos to the AP-1 response ele-
ment on the promoter region of collagen I (Fig. 7C, “IgG”, control IgG;
“input”, positive control). To directly determine AP-1 activation after
CTGF treatment, WI-38 cells were transiently transfected with the
AP-1-luciferase construct as an indicator of AP-1 activation. As shown
in Fig. 7D, WI-38 cell treatment with CTGF (3–100 ng/ml) caused a
concentration-dependent increase in AP-1-luciferase activity (Fig. 7D).
Taken together, these results suggest that AP-1 plays an important role
in CTGF-induced collagen I expression in human lung ﬁbroblasts.
3.6. Rac1, MLK3, and JNK mediate CTGF-induced AP-1 activation
We further examinedwhether activation of AP-1 occurs through the
Rac1/MLK3/JNK signaling pathway. As shown in Fig. 8, transfection of
cells with RacN17 (1 μg), MLK3DN (0.5 μg), JNK1DN (0.5 μg), and
JNK2DN (0.5 μg) all inhibited CTGF-induced AP-1-luciferase activity by
66 ± 19%, 84 ± 16%, 58 ± 18%, and 80 ± 9%, respectively (n = 3).
These results suggest that activation of Rac1/MLK3/JNK is required for
CTGF-induced AP-1 activation in WI-38 cells.
3.7. Collagen I mediates CTGF-induced α-SMA expression
Previous studies demonstrated that CTGF contributes to expression
of α-SMA and the myoﬁbroblast phenotype in tissue repair or develop-
ment of connective tissues [13,14]. Recent study indicated that collagen
is involved in the development of lung ﬁbrosis including ﬁbroblast dif-
ferentiation [20]. Next, to determine whether CTGF-induced collagen I
expression was contributed to ﬁbroblast differentiation, procollagen I
siRNAwas used. Fibroblast differentiation induced by CTGF is character-
ized by the expression of α-SMA. The siRNA experiments revealed that
procollagen I siRNA (50 nM) inhibited CTGF-inducedα-SMA expression
by 90 ± 8% (n = 4) (Fig. 9). To further conﬁrm the result of pro-
collagen I siRNA experiment. We also used procollagen I siRNA to sup-
press collagen I protein expression. We found that procollagen I siRNA
gradually inhibited collagen I protein expression (Fig. 9). Taken to-
gether, these results indicated that induction of collagen I expression
is contributed to CTGF-induced α-SMA expression in WI-38 cells.
4. Discussion
It is known that increased CTGF protein levels occur inmost tissue ﬁ-
brotic diseases and that CTGF plays an important role in various patho-
logical processes. For example, CTGF modulates tissue ﬁbrosis by
ﬁbroblast proliferation and ECM synthesis [42]. A large body of evidence
has accumulatedwhich suggests that collagen plays a pivotal role in lung
ﬁbrosis [19]. Several studies indicated that TGF-β and CTGF can induce
collagen expression in different cell types [9,15]. However, signal trans-
duction events, especially the Rac/MLK3/JNK pathway, which leads to
AP-1 activation and collagen I expression by CTGF, are unclear. In the
present study, our results demonstrate for the ﬁrst time that CTGF acts
through Rac1 to activate the MLK3/JNK signaling cascade, which in
turn initiates AP-1 activation and recruitment to the collagen I promoter,
and ﬁnally induces collagen I expression in human lung ﬁbroblasts.
Rac1was demonstrated to play important roles in promoting growth
cone motility, axonal migration, and dendritic spine morphogenesis in
Fig. 7.Activator protein-1 (AP-1)mediated connective tissue growth factor (CTGF)-induced collagen I expression inWI-38ﬁbroblasts. (A) cells were pretreatedwith an equivalent vehicle
control (DMSO) or curcumin (1–10 μM) for 30 min followed by stimulation with the CTGF (30 ng/ml) for another 4 h. Cells were lysed and then immunoblottedwith antibodies speciﬁc
for collagen I orα-tubulin. Equal loading in each lane is shown by the similar intensities ofα-tubulin. Traces represent results from three independent experiments,which are presented as
themean ± SEM. * p b 0.05, compared to the controlwith theCTGF-treated group. (B) Cellswere treatedwith the vehicle or CTGF (30 ng/ml) for 0–120 min. c-Jun Ser63 phosphorylation
was shown by immunoblotting with an antibody speciﬁc for phosphorylated c-Jun Ser63. Equal loading in each lane is shown by the similar intensities of c-Jun. Traces represent results
from three independent experiments, which are presented as the mean ± SEM. * p b 0.05, compared to the control without CTGF stimulation. (C) Schematic diagram of AP-1-binding
elements and the ChIP primer location on the collagen I promoter. ChIP primer pairs with 523-bp PCR products were designed to amplify DNA corresponding to the putative AP-1-binding
site. Cells were incubatedwith the vehicle or CTGF (30 ng/ml) for 30 min, and then cross-linkedwith formaldehyde at 37 °C for another 10 min. Cell lysates were sonicated and prepared
for the ChIP assay using antibodies speciﬁc for c-Jun and c-Fos. PCR ampliﬁcation using primers designed against AP-1-binding sites was performed. Equal amounts of the soluble cross-
linked chromatins present in each PCRwere conﬁrmed by the product for input. Rabbit polyclonal IgGwas used as a negative control. Input, 1% of sonicated cross-linked chromatins. Typ-
ical traces are representative of three experiments with similar results. (D) Cells were transiently transfectedwith 0.8 μg of AP-1-Luc and 0.1 μg of pBK-CMV-LacZ for 24 h, and then cells
were stimulatedwith 3–100 ngCTGF for another 16 h. Luciferase activitieswere determined as described in “Materials andmethods”. The level of induction of luciferase activitywas com-
pared to that of cellswithout CTGF treatment. Data represent themean ± SEMof three experiments performed in duplicate. * p b 0.05, compared to the control without CTGF stimulation.
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tion factors, including AP-1, and mediates gene expression by various
stimuli [32,43]. Liu et al. [34] demonstrated that activation of Rac1 was
required for collagen expression caused by bleomycin-induced skin ﬁ-
brosis in a mouse model. In addition, sustained activation of Rac1 pro-
moted carbon tetrachloride-induced collagen expression in hepatic
stellate cells and liver ﬁbrosis in mice [44]. In this study, we found that
treating WI-38 cells with CTGF caused activation of Rac1, and a Rac1
dominant negative mutant (RacN17) inhibited CTGF-induced collagen I
expression. These results indicate that Rac1 is required for collagen I ex-
pression caused by the CTGF in human lung ﬁbroblasts.
Activated MLK3 plays a key role in regulating diverse cellular re-
sponses, including cell differentiation and apoptosis, through stimulating
downstream signaling proteins such as JNK [45]. MLK3 activity is nega-
tively regulated by autoinhibition through an interaction with the N-
terminal SH3 domain [28]. In contrast, like many protein kinases, MLK3
is positively regulated by phosphorylation. Within the MLK3 catalyticdomain, the activation loop contains regulatory phosphorylation sites.
A mutagenesis analysis showed that Thr277 and Ser288 residues of
MLK3 are positive regulatory phosphorylation sites [36]. Moreover, a
previous study showed that the activated forms of Rho GTPases, Rac
and Cdc42, interact with MLK3 and promote MLK3 catalytic activity
[27]. In addition, Teramoto et al. [25] demonstrated thatMLK3 activation
is mediated by the Rac1 pathway in COS-7 cells. In this study, we found
that CTGF induced an increase in MLK3 phosphorylation at the Thr277/
Ser281 residues; this effect was markedly attenuated by RacN17. These
results suggest that CTGF-induced MLK3 phosphorylation occurs
through the Rac1 pathway in human lung ﬁbroblasts. Previous reports
indicated that MLK3 is required to induce gene expression by various
stimuli [46,47]. Roy et al. [46] reported that activation of MLK3 is re-
quired for P4 reporter gene expression caused by INF-γ stimulation.
Moreover, MLK3 was shown to be activated by CD3/CD28-induced IL-2
expression in T cells [47]. In this study, we found that CTGF-induced col-
lagen I expression was inhibited by MLK3DN. Moreover, transfection of
Fig. 8. Involvement of Rac1, mixed-lineage kinase 3 (MLK3), and c-Jun N-terminal kinase
(JNK) in connective tissue growth factor (CTGF)-inducedAP-1-luciferase activity inWI-38
ﬁbroblasts. Cells were either transiently transfected with 0.8 μg of AP-1-Luc and 0.1 μg of
pBK-CMV-LacZ or cotransfected with 1 μg of pcDNA (mock), 1 μg of RacN17, 0.5 μg of the
dominant negativemutant ofMLK3 (MLK3DN), 0.5 μg of JNK1DN, or 0.5 μg of JNK2DN for
24 h, and then stimulated with the CTGF (30 ng/ml) for another 16 h. Luciferase activity
was determined as described above. Data presented the mean ± SEM of three experi-
ments performed in duplicate. * p b 0.05, compared to the CTGF-treated group.
Fig. 10. Schematic summary of the signaling pathway involved in connective tissue
growth factor (CTGF)-induced collagen I expression in human lung ﬁbroblasts. The CTGF
induces activation of theRac1/MKL3/JNK/AP-1 cascadewhich results in increased collagen
I expression in human lung ﬁbroblasts (WI-38).
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Taken together, these results indicate that Rac1-dependentMLK3 activa-
tion is involved in CTGF-induced collagen I expression in human lung
ﬁbroblasts.
JNK, a MAPK family member, can be activated by various stimuli
[30,37]. JNK plays an important role in transducing extracellular signals
to cytosolic and nuclear effectors that regulate various cellular re-
sponses, including cell apoptosis, inﬂammation, and gene expres-
sion [48]. The MAPK signaling cascade consists of MAPK, MAPKK, andFig. 9. Involvement of collagen I in connective tissue growth factor (CTGF)-induced α-
smooth muscle actin (α-SMA) expression in WI-38 ﬁbroblasts. Cells were transiently
transfecetd control siRNA (50 nM) or procollagen I siRNA (50 nM) for 24 h. Cellswere stim-
ulated with CTGF (30 ng/ml) for another 48 h, and then α-SMA, collagen I, and α-tubulin
were determined. Traces represent results from four independent experiments, which are
presented as the mean ± SEM. * p b 0.05, compared to the control siRNA group.MAPKKK. All members of this cascade are activated through phosphor-
ylation of speciﬁc residues by their upstream kinases. JNKs are activated
after their dual phosphorylation of threonine and tyrosine byMLK3 and
MKK4/7 kinases [28]. Furthermore, several studies reported JNK-
dependent signaling pathway involvement in collagen I expression by
various stimuli [15,39]. In this study, we found that JNK1DN, JNK2DN,
and a JNK inhibitor (SP600125) all attenuated CTGF-induced collagen I
expression. Moreover, MLK3DN and K252a, a MLK3 inhibitor, blocked
CTGF-induced JNK phosphorylation. These results suggest that MLK3-
dependent JNK activation is essential for collagen I expression stimu-
lated by the CTGF. This is consistent with previous reports that JNK
plays an important role in mediating the effects of bleomycin-induced
collagen I expression in mouse lung and CTGF-induced collagen I ex-
pression in human fetal lung ﬁbroblasts [15]. Furthermore, CTGF-
inducedMLK3 and JNK phosphorylation was attenuated by transfecting
cells with RacN17. Taken together, these results suggest that Rac1-
mediated MLK3 and JNK activation might play an important role in
CTGF-induced collagen I expression in human lung ﬁbroblasts.
The transcription factor AP-1 generally consists of heterodimers of
c-Jun and c-Fos proteins [40]. Recent investigations demonstrated that
JNK plays an important role in AP-1 activation [49,50]. Once activated,
JNK phosphorylates the Ser63 residue of c-Jun and increases AP-1 tran-
scriptional activity to modulate transcription of a number of ﬁbrotic
genes such as collagen [39]. The promoter region of the human collagen
I gene containsmany transcription factor binding sites including c/EBPβ,
Smads, and AP-1 [21]. Of these, the AP-1 site was reported to be critical
for induction of collagen I transcription [39]. In this study, we found that
curcumin, anAP-1 inhibitor, attenuated CTGF-induced collagen I expres-
sion. We also found that CTGF induced increases in c-Jun phosphoryla-
tion and AP-1-luciferase activity. Moreover, results from the ChIP
analysis indicated that c-Jun and c-Fos directly binding to the endoge-
nous collagen I promoter region is caused by CTGF stimulation. Hence,
our data suggest that AP-1 sites on the collagen I promoter play crucial
roles in CTGF-induced collagen I expression in human lung ﬁbroblasts.
Furthermore, we found that transfecting cells with Rac1N17, MLK3DN,
JNK1DN, and JNK2DN all inhibited CTGF-induced AP-1-luciferase acti-
vity. Taken together, these results indicate that Rac1, MLK3, and JNK ac-
tivations are involved in CTGF-induced AP-1 activation in human lung
ﬁbroblasts.
Several studies demonstrated that CTGF plays a critical role in lung
ﬁbrosis [11–14]. Collagen is regarded as a key mediator for TGF-β- or
CTGF-induced ﬁbrogenic effects [15,51]. Previous studies suggested
that collagen-dependent cellular processes known to be involved in
2832 C.-H. Lin et al. / Biochimica et Biophysica Acta 1833 (2013) 2823–2833the development of lung ﬁbrosis including ﬁbroblast proliferation, mi-
gration, differentiation, or ECM synthesis [19,20]. Ruiz and Jarai indicat-
ed that treating normal human lung ﬁbroblasts with collagen I caused
increase in ﬁbroblast migration [52]. However, it has been previously
reported that CTGF can induce temporal procollagen expression, tran-
sient matrix accumulation, and transient lung ﬁbrosis, but is not sufﬁ-
cient to induce progressive ﬁbrosis in rat model [53]. In this study, we
have demonstrated a role of collagen I in mediating the CTGF induced
α-SMA expression, a differentiation marker, in WI-38 cells. We found
that procollagen I siRNA inhibited CTGF-induced α-SMA expression,
suggesting that induction of collagen I expression is contributes to
CTGF-induced ﬁbroblast differentiation.
In conclusion, the current study indicates that treatment of lung ﬁ-
broblasts with CTGF activates the Rac1/MLK3/JNK signaling pathway,
which in turn initiates AP-1 activation and recruitment of c-Jun and
c-Fos to the collagen I promoter, and ﬁnally induces collagen I expres-
sion in human lung ﬁbroblasts. This is the ﬁrst study to demonstrate
that the Rac1-dependentMLK3/JNK/AP-1 signaling pathway is involved
in CTGF-induced collagen I expression in human lung ﬁbroblasts. Fig. 10
shows a schematic representation of the signaling pathway involved in
the expression of collagen I in response to CTGF in human lung ﬁbro-
blasts. Discovery of the signaling pathway of CTGF in collagen I expres-
sion may help elucidate the role of CTGF in lung ﬁbrosis.
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